Eli Lilly named presenting partner of USOPC Team USA Athlete Recovery Program

Lilly expands athlete recovery role with USOPC

Eli Lilly and Company is becoming the presenting partner for the United States Olympic and Paralympic Committee’s Team USA Athlete Recovery Program in a multi‑year collaboration that extends support beyond competition. The deal builds on Lilly’s existing role as an Official Partner in Health Equity and positions the company to underwrite targeted rehabilitation and coordinated, holistic care for athletes managing complex or extended recoveries from Milano Cortina 2026 through the LA28 Games.

The program prioritises long‑term recovery whether athletes return to sport or transition to new careers, offering access to rehabilitation, provider networks, education and outcome measurement. The USOPC pilots the model in 2024 with 10 athletes — six of whom qualify for Paris 2024 and collectively win four medals, including two golds — and now plans to scale the service to reach many more athletes over the next three years. USOPC Chief Medical Officer Dr. Jonathan Finnoff says the initiative provides clinical expertise and coordinated care to help athletes navigate recovery journeys.

Lilly is also committing to storytelling, awareness campaigns and transparent measurement of clinical and functional outcomes, with the USOPC integrating the recovery program into athlete care pathways and reporting progress to stakeholders and fans. Jennifer Oleksiw, Lilly’s global chief customer officer, frames the expanded partnership as a long‑term commitment to holistic athlete health. U.S. Paralympic triathlete Grace Norman credits the Athlete Recovery Program with helping her reach the start line and become Paralympic champion in Paris 2024 after entering the year with an injury.

Lilly confirms upcoming investor engagement

Separately, Lilly announces participation in TD Cowen’s 46th Annual Health Care Conference on March 2, 2026, where CFO Lucas Montarce will appear in a fireside chat. The company makes a live audio webcast available through its investor website and posts a replay for approximately 90 days.

Company emphasises science and access

Lilly reiterates its identity as a medicine company “turning science into healing,” highlighting nearly 150 years of research and a focus on biotechnology, chemistry and genetic medicine. It underscores work on diabetes, obesity, Alzheimer’s disease, immune disorders and difficult‑to‑treat cancers, and says it is committed to diverse clinical trials and making medicines accessible and affordable.